These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35313124)

  • 21. Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
    Linazasoro-Cristóbal G; López Del Val LJ; García Ruiz-Espiga P; López-Manzanares L; Luquin-Piudo MR; Martínez-Castrillo JC; Mir P; Pagonabarraga-Mora J
    Rev Neurol; 2020 Jun; 70(s01):S1-S11. PubMed ID: 32515486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Opicapone for the treatment of Parkinson's disease: real-life data in Spain].
    López-Ariztegui N; Mata-Alvarez Santullano M; Tegel I; Almeida F; Sarasa P; Rojo R; Rico-Villademoros F; Abril-Jaramillo J; Bermejo P; Borrue C; Caballol N; Campins-Romeu M; Clavero P; García-Caldentey J; Gómez-Mayordomo V; Labandeira C; Martí-Andrés G; Martínez-Castrillo JC; Martinez-Poles J; Muñoz T; Salom JM; Valderrama-Martín C; Vinagre-Aragón A
    Rev Neurol; 2021 Dec; 73(s02):S01-S14. PubMed ID: 34897643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Ferreira JJ
    Neurodegener Dis Manag; 2016 Oct; 6(5):349-62. PubMed ID: 27599671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone.
    Jenner P; Rocha JF; Ferreira JJ; Rascol O; Soares-da-Silva P
    Expert Rev Neurother; 2021 Sep; 21(9):1019-1033. PubMed ID: 34525893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opicapone for Parkinson's disease: clinical evidence and future perspectives.
    Leung C; Rascol O; Fabbri M
    Neurodegener Dis Manag; 2021 Jun; 11(3):193-206. PubMed ID: 33745288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
    St Onge E; Vanderhoof M; Miller S
    Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
    Katsaiti I; Nixon J
    J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COMT Inhibitors in the Management of Parkinson's Disease.
    Fabbri M; Ferreira JJ; Rascol O
    CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P
    Eur J Neurol; 2019 Jul; 26(7):953-960. PubMed ID: 30681754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opicapone: Once-Daily COMT Inhibitor for the Treatment of Wearing Off in Parkinson's Disease.
    Craft BM; Baker DE; Levien TL
    Sr Care Pharm; 2022 Feb; 37(2):55-61. PubMed ID: 35082010
    [No Abstract]   [Full Text] [Related]  

  • 33. [Relevance of COMT inhibitors in the treatment of motor fluctuations].
    Jost WH; Buhmann C; Classen J; Eggert K; Kohl Z; Outeiro T; Tönges L; Woitalla D; Reichmann H
    Nervenarzt; 2022 Oct; 93(10):1035-1045. PubMed ID: 35044481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.
    Annus Á; Vécsei L
    Drug Des Devel Ther; 2017; 11():143-151. PubMed ID: 28123288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The launch of opicapone for Parkinson's disease: negatives versus positives.
    Castro Caldas A; Teodoro T; Ferreira JJ
    Expert Opin Drug Saf; 2018 Mar; 17(3):331-337. PubMed ID: 29415596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opicapone (Ongentys) - a COMT inhibitor for Parkinson's disease.
    Med Lett Drugs Ther; 2021 Jan; 63(1615):3-5. PubMed ID: 33646998
    [No Abstract]   [Full Text] [Related]  

  • 37. Opicapone for the Treatment of Parkinson's Disease "Off" Episodes: Pharmacology and Clinical Considerations.
    Berger AA; Robinson C; Winnick A; Izygon J; Jacob BM; Noonan MJ; Kaye AD; Kaye JS; Kaye AM; Cornett EM; Shah RJ; Viswanath O; Urits I
    Clin Drug Investig; 2022 Feb; 42(2):127-135. PubMed ID: 34935105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opicapone for the treatment of Parkinson's disease.
    Rodrigues FB; Ferreira JJ
    Expert Opin Pharmacother; 2017 Mar; 18(4):445-453. PubMed ID: 28234566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial.
    Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Moreira J; Pereira A; Rocha JF; Soares-da-Silva P
    Neurol Ther; 2022 Sep; 11(3):1409-1425. PubMed ID: 35705887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
    Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
    Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.